Krystal Biotech awarded director Janney Daniel 1,658 derivative securities at $0 per share on 2026-09-14. The terms matter to investors because they identify a zero-price award or grant, rather than a purchase or sale, and specify the security type and recipient tied to the company.
Key Highlights
- Janney Daniel is identified as a director of Krystal Biotech, Inc.
- The transactions carry SEC transaction code A.
- Krystal Biotech, Inc. is listed on Nasdaq under KRYS.
Krystal Biotech, Inc. (NASDAQ: KRYS) awarded Janney Daniel 1,658 derivative securities at $0 per share on 14 September 2026. Daniel is identified as a director of Krystal Biotech, Inc.
1,658 Derivative Securities Awarded
The award was recorded through two transactions carrying SEC transaction code A. The instrument involved was derivative securities, and the disclosed price was $0 per share. Janney Daniel was the named recipient. The transaction date was 14 September 2026. Krystal Biotech, Inc. linked the award to its director, Janney Daniel. The disclosed terms identify the security type, transaction classification and price attached to the award. Transaction code A denotes an award, grant, or other Acquisition from the company.
FAQs
Q: What did Janney Daniel receive from Krystal Biotech?
A: Janney Daniel received a total of 1,658 derivative securities from Krystal Biotech across two separate transactions. The filing records all transactions under code A at $0 per share on 14 September 2026.
Q: Was Janney Daniel’s Krystal Biotech transaction a stock purchase?
A: The filing identifies two transactions carrying SEC code A and reports derivative securities at $0 per share. It does not provide a stock-purchase description.
Q: When did the Krystal Biotech insider award occur?
A: The filing reports the award on 14 September 2026. It identifies Janney Daniel as a director of Krystal Biotech, Inc. and states that the securities were reported in two transactions.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.